AstraZeneca's Lynparza Gets FDA Nod for Pancreatic Cancer
ZacksDecember 31, 2019, 1:55 PM UTC. AstraZeneca AZN and Merck MRK announced that the FDA has approved their PARP inhibitor, Lynparza, as maintenance treatment for BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) in patients whose disease has progressed at least 16 weeks following first-line platinum-based chemotherapy regimen. With this approval, Lynparza becomes the first PARP inhibitor to be approved for treating biomarker-selected patients with advanced pancreatic cancer. In the first nine months, sales from the drug grew 93% year over year to $847 million on the back of several label expansions, especially first-line ovarian cancer. AstraZeneca expects it to reach blockbuster status this year. Lynparza enjoys advantage in the PARP inhibitor segment as it is approved for the most number of oncology indications. AstraZeneca PLC Price. AstraZeneca PLC price | AstraZeneca PLC Quote.